NEW YORK (GenomeWeb) – Transfusion and transplantation diagnostics firm Immucor announced on Wednesday its acquisition of Sentilus for an undisclosed amount.
Durham, NC-based Sentilus was founded in 2012 and is developing an inkjet-printed antibody microarray-based technology called Femtoarrays for use in in vitro diagnostics, including transfusion diagnostics.
Immucor President and CEO William Hawkins said that the Femtoarrays technology "will underpin a full complement of next-generation immunohematology assays. Additionally, we believe the technology has the potential for broad application throughout in vitro diagnostics."
Immucor is headquartered in Norcross, Ga. In May, the US Food and Drug Administration approved the Immucor Precise Type Human Erythrocyte Antigen Molecular BeadChip Test for blood compatibility determination.